Microsoft vs Zimmer Biomet Holdings Inc — how do they compare? Microsoft trades at $396.4 (market cap $2.99T), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Microsoft is far larger — about 172.2× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.07%). Which is the better fit depends on your goals.
| MSFT | ZBH | |
|---|---|---|
Market Cap | $2.99T | $17.36B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $107.71 |
52-Week Low | $352.83 | $79.58 |
Enterprise Value | $2.97T | $24.40B |
Dividend Yield | 0.9% | 1.07% |
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $397.75, up 1.0% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $281.72B in 2025, with net income of $101.83B, and the company has beaten EPS estimates for three consecutive quarters. Analysts maintain an 80.49% buy rating with a consensus price target of $546.70, highlighting AI leadership through Azure and Copilot.
The outlook remains positive given robust earnings growth and AI-driven opportunities, but risks include elevated capital expenditure concerns and competitive pressures. Valuation metrics like a P/E of 23.96 and P/S of 9.43 suggest the stock is fairly priced, supporting a long-term bullish view tempered by near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →